BioCentury
ARTICLE | Company News

Indivior's Sublocade MAT to compete with Alkermes’ Vivitrol

December 1, 2017 10:13 PM UTC

FDA approved once-monthly subcutaneous Sublocade buprenorphine (RBP-6000) from Indivior plc (LSE:INDV) to treat opioid use disorder. The company said it expects to launch the drug next quarter at a wholesale acquisition cost (WAC) of $1,580 per month. The WAC is the same for both 100 and 300 mg dose levels.

Sublocade, an opioid agonist, will compete with Vivitrol naltrexone, an opioid antagonist from Alkermes plc (NASDAQ:ALKS) that is also dosed monthly. The WAC for Vivitrol is $1,309. Alkermes has been criticized by members of Congress for its Vivitrol pricing and marketing practices. ...